Chloroquine Moves To Top of COVID-19 Clinical Trial List
Bayer, Novartis, Sanofi, Teva And Mylan Donating Antimalarial
Executive Summary
Many hopes for an effective coronavirus treatment are being pinned on chloroquine, not least those of President Trump, and pharma companies are supplying the antimalarial to the US at no cost for use in clinical trials.
You may also be interested in...
How Novartis Is Helping Staff Through COVID-19 Crisis
Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.
Novartis CEO Backs Malaria Drug Against COVID-19
A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best placed to provide the quickest benefit.
FDA ‘Exception’ For Ipca’s Chloroquine/HCQ Amid Supply Plans From Others
Import alert hit-Ipca gets a temporary reprieve from US FDA for supplies of hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials in the spotlight as potential treatments for COVID-19. But with many firms committing to supplies/donations, analysts appear to be tempering enthusiasm for large windfall gains for the Indian firm.